Technical Data
AGR2 (AG-2, Anterior Gradient 2, Secreted Cement Gland Protein XAG-2 Homolog, HPC8)
The anterior gradient protein-2 (AGR2) is a cancer cell marker specifically up-regulated in response to depletion of serum and oxygen. It has been identified as a tumor marker in primary and secondary cancer lesions, and as a marker for detection of circulating tumor cells. Elevated levels of AGR2 are known to increase the metastatic potential of cancer cells (1). Specifically, AGR2 may serve as a useful molecular marker and/or potential therapeutic target for hormone-responsive breast tumors (2). AGR2 expression promotes tumor growth in esophageal adenocarcinoma cells as well. Expression was detected in proliferating and differentiated intestinal cells of secretory lineage, suggesting that AGR2 may be important for the growth and development of the intestine as well as esophageal adenocarcinomas (3).

Suitable for use in Western Blot, Immunohistochemistry, Immunocytochemistry. Other applications not tested.

Recommended Dilution:
Western Blot: 1:500-2000
Immunohistochemistry: 1:100-250
Immunocytochemistry 1:100
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. For long-term storage, store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Manufactured incorporating RabMAb® technology under Epitomics US patents, No 5,675,063 and 7,429,487, owned by Abcam.
100ul-20°CBlue IceHumanRabbit
Not determined
A synthetic peptide corresponding to residues in human AGR2.
Supplied as liquid in 50mM Tris-Glycine, pH 7.4, 0.15M sodium chloride, 40% glycerol, 0.01% sodium azide, 0.05% BSA.
Recognizes human AGR2. Species Crossreactivity: rat.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Zweitzig DR, et al. Mol Cell Biochem. 306(1-2) :255-60, 2007. 2. Fletcher GC, et al. Br J Cancer 88(4): 579-85, 2003. 3. Wang Z, et al. Cancer Res. 68(2): 492-7, 2008